Incremental value of cardiac biomarkers and cancer-related factors beyond SCORE2 for prediction of cardiovascular events
Cancer therapy-related cardiovascular (CV) disease is an increasing cause of morbidity and mortality among cancer survivors. Current guidelines recommend CV risk prediction tools such as SCORE2; however, these do not account for cancer-specific factors or cardiac biomarkers. Whether incorporating cardio-oncology...